Diarylquinoline - TB Alliance
Alternative Names: TBAJ-587Latest Information Update: 20 Mar 2025
At a glance
- Originator European Regimen Accelerator for Tuberculosis; Global Alliance for TB Drug Development
- Class Antituberculars; Diarylquinolines; Ethers; Fluorinated hydrocarbons; Pyridines; Small molecules
- Mechanism of Action Adenosine triphosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Tuberculosis
Most Recent Events
- 20 Mar 2025 Phase-I development is ongoing in Tuberculosis in Netherlands (PO, Suspension) (AB Alliance pipeline, March 2025)
- 28 Nov 2024 No recent reports of development identified for phase-I development in Tuberculosis in Netherlands (PO, Suspension)
- 27 Feb 2023 Global Alliance for TB Drug Development completes phase-I development in Tuberculosis in Netherlands (PO, Suspension) (NCT04890535)